HIV Glasgow 2022 Symposium - The Devil Wears GP120

What's New

• To stay updated on the relevant developments, make sure you are signed up for our newsletter.

About the Program

HIV pathogenesis remains an intriguing but not fully understood phenomenon. Although great strides have been made in the last 30 years, much remains to be discovered. GP120 plays a major role in HIV binding to target cells, but recent studies suggest GP120 may play a much greater role in HIV interactions with the immune system. An improved understanding of these interactions may help overcome some of the remaining unmet needs of people living with HIV.

One such example might be improving the immune reconstitution of patients with poor or partial CD4 responses to suppressive therapy. Although CD4 cells and CD4/CD8 ratios improve in most patients after HIV RNA suppression is maintained, these responses can be blunted in highly treatment experienced patients of those starting therapy with very low CD4 counts. GP 120 may be playing a role in these patients, and its inhibition might provide clinical benefit. Additional negative GP120 effects on immune and inflammatory responses might be favorably manipulated with drugs targeting this molecule. This program aims to educate clinicians on recent advances in the study of GP120, and review both basic science as well as clinical data relevant to the topic.

General Information

Practical Information